For the quarter ending 2025-09-30, MNPR has $144,197,278 in assets. $2,639,430 in debts. $127,677,360 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 127,677,360 | 39,501,936 | ||
| Investments | 15,998,427 | 13,748,473 | ||
| Other current assets | 414,825 | 497,294 | ||
| Total current assets | 144,090,612 | 53,747,703 | ||
| Operating lease right-of-use asset | 106,666 | 118,170 | ||
| Total assets | 144,197,278 | 53,865,873 | ||
| Accounts payable, accrued expenses and other current liabilities | 2,568,549 | 1,583,613 | ||
| In-process r and d accrued expenses | 0 | 0 | ||
| Total current liabilities | 2,568,549 | 1,583,613 | ||
| Operating lease liability - non-current | 70,881 | 80,366 | ||
| Total liabilities | 2,639,430 | 1,663,979 | ||
| Common stock, par value of 0.001 per share, 40,000,000 shares authorized, 6,662,930 and 6,102,560 shares issued and outstanding at september 30, 2025, and december 31, 2024, respectively | 6,663 | 6,127 | ||
| Additional paid-in capital | 225,848,222 | 132,989,324 | ||
| Accumulated other comprehensive income | 11,698 | 77,577 | ||
| Accumulated deficit | -84,308,735 | -80,871,134 | ||
| Total stockholders equity | 141,557,848 | 52,201,894 | ||
| Total liabilities and stockholders equity | 144,197,278 | 53,865,873 | ||
Monopar Therapeutics (MNPR)
Monopar Therapeutics (MNPR)